Two prominent congressional Democrats this week wrote to eight pharmaceutical company CEOs, urging them to remove 130 patents ...
And they don't really have the inside view of what's happening at the FDA.” Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, ...
And they don't really have the inside view of what's happening at the FDA.” Gabriel: If drug manufacturers don’t remove their junk patent listings, they’ll open themselves up to antitrust lawsuits, ...
"Teva stifled would-be generic competitors to QVAR because the drug laws do not allow for generic substitution of a given ...
The Federal Trade Commission (FTC) recently challenged over 100 drug patent listings and sent warning letters to 10 drug manufacturers of products ranging from inhalers to EpiPens. Putting drugmakers ...
But now, the FTC says drugmakers are ... So, they end up waiting out the patent and that can take years. McGrevy: Can you give us an example of these junk patents? Gabriel: For example, some ...
The Federal Trade Commissioner Lina Khan has chimed in as she targets “improper or inaccurate patent listings ... to what Congress is proposing, the FTC is directly challenging drugmakers ...
Members of the Senate Judiciary Committee grilled the drug industry trade group about whether alleged abuse of the patent system ... Related: FTC targets 300 Big Pharma 'junk patents,' sends ...
Outrage from legions of Beyoncé and Taylor Swift fans about hidden concert ticket fees helped spark a national conversation around “junk fees." It has even filtered into the 2024 election cycle.